News coverage about Catabasis Pharmaceuticals (NASDAQ:CATB) has been trending somewhat positive recently, Accern Sentiment Analysis reports. Accern identifies positive and negative news coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Catabasis Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned headlines about the biotechnology company an impact score of 47.3828613018893 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
Here are some of the headlines that may have effected Accern Sentiment’s analysis:
- Catabasis Pharmaceuticals, Inc. (CATB) Short Interest Down 62.5% in October (americanbankingnews.com)
- Catabasis Pharmaceuticals, Inc. (CATB) Receives Average Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Edited Transcript of CATB earnings conference call or presentation 9-Nov-17 9:30pm GMT (finance.yahoo.com)
- Investor Network: Catabasis Pharmaceuticals Inc to Host Earnings Call (finanznachrichten.de)
- Catabasis Pharmaceuticals, Inc. (CATB) Issues Earnings Results (americanbankingnews.com)
Shares of Catabasis Pharmaceuticals (NASDAQ:CATB) traded down $0.12 during trading on Tuesday, reaching $1.70. 359,600 shares of the company’s stock were exchanged, compared to its average volume of 1,081,720. Catabasis Pharmaceuticals has a 52 week low of $1.08 and a 52 week high of $5.51.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its quarterly earnings data on Thursday, November 9th. The biotechnology company reported ($0.31) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.33) by $0.02. The firm had revenue of $0.25 million for the quarter. sell-side analysts expect that Catabasis Pharmaceuticals will post -1.42 earnings per share for the current year.
A number of brokerages recently weighed in on CATB. HC Wainwright increased their price target on shares of Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research note on Monday, August 14th. Zacks Investment Research cut shares of Catabasis Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Monday, October 16th. Citigroup Inc. set a $3.50 price target on shares of Catabasis Pharmaceuticals and gave the stock a “hold” rating in a research note on Thursday, October 5th. Cowen and Company reiterated a “market perform” rating and set a $2.00 price target on shares of Catabasis Pharmaceuticals in a research note on Friday, October 6th. Finally, Oppenheimer Holdings, Inc. increased their price target on shares of Catabasis Pharmaceuticals from $4.00 to $7.00 and gave the stock an “outperform” rating in a research note on Thursday, October 5th. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. The company has an average rating of “Buy” and an average price target of $5.42.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.